SCI Pharmtech Inc

SCI Pharmtech, Inc. is a Taiwan-based company that researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. Its API portfolio includes adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCl, sodium valproate, thiopental, and valproic acid. The company also develops benserazide, CBN, and CBDv, and provides intermediate products such as diethyl isobutyl malonate, benzhydrylamine, 1-benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GlcNAc, and UDP-GalNAc. It also offers customized production services and operates in Italy, Spain, the Netherlands, Belgium, the United States, Japan, Germany, Taiwan, Switzerland, and internationally. Incorporated in 1987, SCI Pharmtech is based in Taoyuan City, Taiwan.